Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant December 20, 2021
Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners December 9, 2021
Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics December 8, 2021
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate December 1, 2021
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum November 23, 2021
Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics. October 4, 2021
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate September 15, 2021
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants August 30, 2021
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines July 27, 2021
